Jefferies Group’s TherapeuticsMD TXMD Stock Holding History

Jefferies Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,184	Closed	-$63K	–	2039
2020 Q1	$63K	Sell	1,184 -8,036	-87%	-$797K	﹤0.01%	1852
2019 Q4	$1.12M	Buy	+9,220	New	+$1.33M	0.01%	1401
2019 Q3	–	Sell	-850	Closed	-$111K	–	3066
2019 Q2	$111K	Buy	+850	New	+$152K	﹤0.01%	2264
2016 Q1	–	Sell	-1,230	Closed	-$638K	–	2569
2015 Q4	$638K	Buy	+1,230	New	+$454K	﹤0.01%	1392
2015 Q3	–	Sell	-690	Closed	-$271K	–	3032
2015 Q2	$271K	Buy	+690	New	+$243K	﹤0.01%	1827
2014 Q4	–	Sell	-504	Closed	-$117K	–	2342
2014 Q3	$117K	Hold	504	–	–	﹤0.01%	1899
2014 Q2	$111K	Buy	+504	New	+$112K	﹤0.01%	1862

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group's TXMD Position: Q2 2020 in Review

Jefferies Group sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 1,401 shares — an estimated $74K sold.

Jefferies Group first reported a position in TXMD in Q1 2014 and held it in 12 quarters. The position peaked at $7.66M in Q1 2014. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

Jefferies Group reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
Jefferies Group sold 1,401 TherapeuticsMD shares in Q2 2020, an estimated $74K.
Jefferies Group first reported a position in TherapeuticsMD in Q1 2014 and held it in 12 quarters.
Jefferies Group's TherapeuticsMD position peaked at $7.66M in Q1 2014.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.